Milazzo L, Corbellino M, Foschi A, Micheli V, Dodero A, Mazzocchi A, Montefusco V, Zehender G, Antinori S
Section of Infectious Diseases and Immunopathology, Department of Clinical Sciences L. Sacco, Università degli Studi di Milano, L. Sacco Hospital, Milan, Italy.
Transpl Infect Dis. 2012 Feb;14(1):95-8. doi: 10.1111/j.1399-3062.2011.00659.x. Epub 2011 Jul 12.
Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.
对于乙肝核心抗体阳性的异基因造血干细胞移植（HSCT）受者，推荐使用拉米夫定（LAM）进行预防，但预防措施开始的最佳时机和持续时间仍不清楚。此外，考虑到与乙肝病毒再激活（HBV-R）相关的高死亡率，应考虑使用最有效和长期有效的抗病毒方案。我们在此报告一例非霍奇金淋巴瘤接受HSCT的患者，在长期使用LAM预防后出现迟发性HBV-R，该患者通过包括恩替卡韦和替诺福韦酯在内的联合抗病毒方案成功治疗。
